CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety of combining the drugs gemtuzumab
ozogamicin (GO) with CPX-351 in order to treat the disease, as well as to find the maximum
tolerated dose level and recommended Phase 2 dose level of GO with a fixed dose of CPX-351.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute